Stockscreener 앱 받기
3.07
4.78%
0.14
시간 외 거래:
3.08
0.01
+0.33%
전일 마감가:
$2.93
열려 있는:
$2.97
하루 거래량:
689.32K
Relative Volume:
1.64
시가총액:
$101.98M
수익:
$66.16M
순이익/손실:
$128.94M
주가수익비율:
0.9647
EPS:
3.1823
순현금흐름:
$152.08M
1주 성능:
+10.83%
1개월 성능:
+27.39%
6개월 성능:
-10.50%
1년 성능:
+67.76%
1일 변동 폭
$2.9432
$3.15
1주일 범위
$2.72
$3.15
52주 변동 폭
$1.70
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
명칭
Fortress Biotech Inc
전화
781-652-4500
주소
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
3.07 | 95.01M | 66.16M | 128.94M | 152.08M | 3.1823 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-15 | 재개 | ROTH MKM | Buy |
| 2022-08-04 | 개시 | Ladenburg Thalmann | Buy |
| 2020-10-02 | 개시 | The Benchmark Company | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2018-02-28 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
| 2017-03-22 | 개시 | JMP Securities | Mkt Outperform |
| 2016-10-03 | 개시 | ROTH Capital | Buy |
모두보기
Fortress Biotech Inc 주식(FBIO)의 최신 뉴스
(FBIOP) Volatility Zones as Tactical Triggers - Stock Traders Daily
FBIOP Q4 2025 Earnings: Preferred Stock Reports Wider-than-Expected Loss Amid Narrowing Pipeline Progress - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Edges Higher Before Resistance TestPut Support - newsline.com
FBIOP Q4 2025 Earnings: Preferred Stock Faces EPS Miss as Company Reports LossEPS Revision Trend - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Faces Resistance, Slides 2.3% in Quiet SessionProtective Put - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Pulls Back 2.3% as Shares Approach Key SupportDescending Triangle - newsline.com
Price-Driven Insight from (FBIOP) for Rule-Based Strategy - Stock Traders Daily
Fortress Biotech Inc stock (US32015L1035): Nasdaq-listed biotech moves in low-volume trade ahead of - AD HOC NEWS
Fortress Biotech Preferred Stock (FBIOP) Surges 5.19%, Nears Key Resistance at $21.5BPI Bear Confirmed - newsline.com
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO) - Seeking Alpha
FBIO Q4 2025 Earnings: EPS Misses Estimates, Stock Moves HigherEarnings Quality Analysis - newsline.com
FBIO Q4 2025 Earnings: EPS Misses Estimates as Revenue Remains AbsentEarnings Seasonality - The Legal Advocate
Fortress Biotech Preferred (FBIOP) Rises 2.37%; Support and Resistance in FocusSynthetic Long - The Legal Advocate
Earnings call transcript: Journey Medical Q1 2026 shows 21% revenue rise By Investing.com - Investing.com South Africa
Earnings call transcript: Journey Medical Q1 2026 shows 21% revenue rise - Investing.com Canada
FBIOP Q4 2025 Earnings: Preferred Stock Reports Negative EPS Surprise Amid No Revenue Disclosure - newsline.com
Fortress Biotech Preferred Shares (FBIOP) Advance 2.45% as Support Holds Near $16Dark Pool Prints - The Legal Advocate
FBIO Q4 2025 Earnings: Deep EPS Miss Highlights Challenges for Pre-Revenue BiotechTrough Earnings Signal - Newser
(FBIOP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Fortress Biotech Preferred Stock (FBIOP) Q4 2025 Earnings: EPS Misses Estimates by Over 108%Community Sell Signals - Newser
Fortress Biotech (FBIO) Gains 1.62% as Shares Approach Key Resistance at $2.97Stock Analysis - Newser
Fortress Biotech Inc. (FBIO) Moves Higher as Buyers Defend Key Support LevelLarge Cap Trends - The Legal Advocate
FBIO Q4 2025 Earnings: Significant EPS Surprise Miss Amid Limited Revenue DisclosureOne-Time Loss Impact - newsline.com
Fortress Biotech (FBIO) Q4 2025 Results Miss Estimates — EPS $-0.01 vs $0.11Consensus Beat Rate - Newser
FBIOP Stock Price, Quote & Chart | FORTRESS BIOTECH INCFBIO 9 3/8 PERP (NASDAQ:FBIOP) - ChartMill
Fortress Biotech (FBIO) Q4 2025 Earnings: Miss Sparks ConcernGAAP Earnings Report - Newser
Fortress Biotech (FBIO) Q4 2025 Miss: What Went WrongInterim Report - Newser
Journey Medical CEO to join online talk at A.G.P. health event - Stock Titan
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference - Sahm
A. G. P. Maintains Fortress Biotech(FBIO.US) With Buy Rating, Raises Target Price to $5 - Moomoo
Why Fortress Biotech (FBIO) Just Surged +5.81% — Key Levels Ahead 2026-05-18Factor Timing - Newser
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease - Stocktwits
Number of shareholders of Fortress Biotech, Inc. – NASDAQ:FBIO - TradingView
Fortress Biotech, Inc.9.375% Series A Cumulative Redeemable Perpetual Preferred Stock - TradingView
Fortress Biotech stock (US32015L1035): FDA setback hits Menkes drug while investors eye next catalys - AD HOC NEWS
Fortress Biotech Inc at Planet MicroCap Showcase Virtual Investor Conference 2020 Transcript - GuruFocus
Highbridge (FBIO) reports 2.73M warrant-backed shares, 7.8% stake - Stock Titan
FBIOP | Fortress Biotech, Inc. 9.375% Insider Trading - Quiver Quantitative
Fortress Biotech (FBIO) Q1: EPS $2.82 Beats Est. -$0.22; Revenue - GuruFocus
Fortress Biotech Q1 2026 Earnings Call Transcript - MarketBeat
Fortress Biotech: Q1 Earnings Snapshot - marketscreener.com
Fortress Biotech, Inc. 1Q 2026: Revenue $15.92M, Net income $110.37M, EPS $2.82— 10-Q Summary - TradingView
Fortress Biotech posts $108.4M net income in Q1 2026, revenue $16.0M - TradingView
Priority review voucher sale drives Fortress Biotech (FBIO) Q1 2026 profit and cash surge - Stock Titan
Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fortress Biotech (NASDAQ: FBIO) turns Q1 2026 profit after $205M PRV sale - Stock Titan
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech stock (US32015L1035): Q1 earnings miss on revenue, but EMROSI shows momentum - AD HOC NEWS
FBIO: Q1 2026 revenue rose 21% to $16M, driven by EMROSI growth and expanding market access - TradingView
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - marketscreener.com
(FBIOP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Fortress Biotech Inc (FBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):